Evidence map›Paper›PMID 24949448›Full record

ReviewBioMed research international2014

Immunomodulation of nanoparticles in nanomedicine applications.

Qing Jiao, Liwen Li, Qingxin Mu, Qiu Zhang

Abstract readReview
In one paragraph

Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Harnessing Nanocarriers to Advance Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Synthesis of immunomodulatory biomimetic lipid polymer hybrid nanoparticles and application of zebrafish larvae in immunomodulation screening.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2025
    Article
  4. Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Generation of multi-layered protein bodies inFrontiers in plant science · 2023
    Article
  12. Review
  13. Review
  14. 2D Materials for Cardiac Tissue Repair and Regeneration.Frontiers in cardiovascular medicine · 2022
    Review
  15. Role of Antimicrobial Drug in the Development of Potential Therapeutics.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qing JiaoSchool of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China.
Liwen LiSchool of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China.
Qingxin MuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA ; Department of Materials Science & Engineering, University of Washington, Seattle, WA 98125, USA.
Qiu ZhangSchool of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticles (NPs) have promising applications in medicine. Immune system is an important protective system to defend organisms from non-self matters. NPs interact with the immune system and modulate its function, leading to immunosuppression or immunostimulation. These modulating effects may bring benefits or danger. Compositions, sizes, and surface chemistry, and so forth, affect these immunomodulations. Here we give an overview of the relationship between the physicochemical properties of NPs, which are candidates to be applied in medicine, and their immunomodulation properties.

Indexed as

NanomedicineHumansImmunizationImmunomodulationImmunosuppression TherapyNanoparticles

Identifiers

PMID24949448
PMCPMC4052466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.